glp 1 tri LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept: Cell Metabolism Navigate nutrition with confidence with
Description
GLP-1s are diabetes drugs that are exploding in popularity because of their weight loss properties
Metabolic-related diseases, including obesity and types 1 and 2 diabetes, among others, have become major health problems worldwide, with a rapid increase in
Whilst further evidence is required to support their clinical use, preclinical and early clinical trial results are encouraging.
Updated series per request
GLP-1 drugs like Ozempic have transformed weight loss in the U.S., with nearly 12% of Americans having tried them, according to a new RAND report
